99-25276. Proposed Vaccine Information Materials for Use With Oral Poliovirus Vaccine (OPV)  

  • [Federal Register Volume 64, Number 188 (Wednesday, September 29, 1999)]
    [Notices]
    [Pages 52596-52597]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 99-25276]
    
    
    
    [[Page 52595]]
    
    _______________________________________________________________________
    
    Part III
    
    
    
    
    
    Department of Health and Human Services
    
    
    
    
    
    _______________________________________________________________________
    
    
    
    Centers for Disease Control and Prevention
    
    
    
    _______________________________________________________________________
    
    
    
    Proposed Vaccine Information Materials for Use With Oral Poliovirus 
    Vaccine (OPV); Notice
    
    Federal Register / Vol. 64, No. 188 / Wednesday, September 29, 1999 / 
    Notices
    
    [[Page 52596]]
    
    
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Centers for Disease Control and Prevention
    
    
    Proposed Vaccine Information Materials for Use With Oral 
    Poliovirus Vaccine (OPV)
    
    AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
    Health and Human Services (HHS).
    
    ACTION: Notice with comment period.
    
    -----------------------------------------------------------------------
    
    SUMMARY: On September 2, 1999, the Centers for Disease Control and 
    Prevention (CDC) published a Federal Register notice seeking comment on 
    proposed revised vaccine information materials for use effective 
    January 1, 2000, when the routine polio immunization schedule changes 
    to an all inactivated poliovirus vaccine (IPV) schedule. With this 
    notice, CDC seeks written comment on proposed supplemental vaccine 
    information materials for use in those limited circumstances where oral 
    poliovirus vaccine (OPV) will still be acceptable.
    
    DATES: Written comments are invited and must be received on or before 
    November 29, 1999.
    
    ADDRESSES: Written comments should be addressed to Walter A. Orenstein, 
    M.D., Director, National Immunization Program, Centers for Disease 
    Control and Prevention, Mailstop E-05, 1600 Clifton Road, N.E., 
    Atlanta, Georgia 30333.
    
    FOR FURTHER INFORMATION CONTACT: Walter A. Orenstein, M.D., Director, 
    National Immunization Program, Centers for Disease Control and 
    Prevention, Mailstop E-05, 1600 Clifton Road, N.E., Atlanta, Georgia 
    30333, telephone (404) 639-8200.
    
    SUPPLEMENTARY INFORMATION: Under the National Childhood Vaccine Injury 
    Act of 1986 (42 U.S.C. 300aa-26), the Centers for Disease Control and 
    Prevention (CDC) develops and revises vaccine information materials for 
    those vaccines covered under the National Vaccine Injury Compensation 
    Program. As provided under that law, all health care providers in the 
    United States, whether public or private, must distribute copies of 
    these materials to any patient (or to the parent or legal 
    representative in the case of a minor) prior to administering any of 
    the covered vaccines.
        On September 2, 1999, CDC published a Federal Register notice (64 
    FR 48238) seeking comment on proposed revised vaccine information 
    materials for use effective January 1, 2000, when the routine polio 
    immunization schedule changes to an all inactivated poliovirus vaccine 
    (IPV) schedule. (See the September 2 notice for a description of the 
    statutory requirements for development and use of the vaccine 
    information materials. Also, see that notice for an explanation of the 
    revisions in the CDC-recommended schedule for use of polio vaccines.)
        As listed in the September 2 Federal Register notice, as of January 
    1, 2000, use of OPV will only be acceptable in the following special 
    circumstances:
        (1) Mass immunization campaigns to control outbreaks due to wild-
    type poliovirus;
        (2) Unimmunized children where travel to polio-endemic areas is 
    imminent (i.e. in less than four weeks) may receive OPV for the first 
    dose;
        (3) Children of parents who do not accept the recommended number of 
    vaccine injections may receive OPV only for dose 3 or 4 or both. (OPV 
    should be administered only after discussion of the risks of OPV 
    vaccine-associated poliomyelitis.); and
        (4) OPV may be administered when the vaccinee has had a life-
    threatening allergic reaction to any component of IPV.
        With this notice, CDC seeks written comment on proposed 
    supplemental vaccine information materials for use in these limited 
    circumstances where oral poliovirus vaccine (OPV) will still be 
    acceptable.
    
    Proposed Supplemental Polio Vaccine Information Materials--OPV
    
        We invite written comment on the proposed supplemental vaccine 
    information materials that follow, entitled ``Oral Polio Vaccine: What 
    You Need to Know.'' Comments submitted will be considered in finalizing 
    these supplemental materials. As required under the National Childhood 
    Vaccine Injury Act, prior to finalizing these materials CDC also will 
    consult with the Advisory Commission on Childhood Vaccines, appropriate 
    health care provider and parent organizations, and the Food and Drug 
    Administration.
    
    Oral Polio Vaccine: What You Need To Know
    
    1. What Is Polio?
    
        Polio is a disease caused by a virus. It can get into a child's (or 
    adult's) body, usually through the mouth. Sometimes it does not cause 
    serious problems. But sometimes it causes paralysis (can't move arm or 
    leg), and sometimes it kills its victims.
        Polio used to be very common in the United States. It paralyzed and 
    killed thousands of children each year before we had a vaccine for it.
    
    2. Why Get Vaccinated?
    
        Polio vaccine can prevent polio.
        History: A 1916 polio epidemic in the United States killed 6,000 
    people and paralyzed 27,000 more. In the early 1950's there were more 
    than 20,000 cases of polio each year.
        Polio vaccine was introduced in 1955. By 1960 the number of cases 
    had dropped to about 3,000, and by 1979 there were only about 30. This 
    change would not have been possible without polio vaccine.
        Today: No wild polio has been reported in the United States for 
    over 20 years. But the disease is still common in some parts of the 
    world. It would only take one case of polio from another country to 
    bring the disease back if we were not protected by vaccine. Until the 
    disease is gone from the whole world, we should keep getting our 
    children vaccinated.
    
    3. Two Types of Polio Vaccine
    
        There are two types of polio vaccine:
    
    IPV (Inactivated Polio Vaccine): A shot.
    
        IPV is recommended for almost all people. It works very well to 
    protect people from paralytic polio.
    
    OPV (Oral Polio Vaccine): Drops, by mouth.
    
        OPV works very well, especially in preventing polio outbreaks. It 
    is due to OPV that there is no polio in the United States today. But it 
    can also actually cause polio. This is rare, but with the risk of polio 
    extremely low in the U.S., OPV is no longer recommended except in 
    special situations.
        This statement is about Oral Polio Vaccine. You can also request a 
    copy of the Vaccine Information Statement that describes the routine 
    all-IPV schedule.
    
    4. Who Should Use Oral Polio Vaccine (OPV) and When?
    
        OPV is no longer recommended for routine use in the United States. 
    It may be used only in certain limited circumstances:
        (1) Mass immunization campaigns to control polio outbreaks;
        (2) Unimmunized people who plan to travel within 4 weeks to 
    countries where polio is common. These people may get OPV for the first 
    dose;
        (3) Children whose parents want them to get fewer injections. These 
    children should get IPV for the first two doses of the polio vaccine 
    series, but may get OPV for the 3rd or 4th dose, or both;
        (4) People with a life-threatening allergy to a component of IPV. 
    These people may get OPV instead.
        If you, or your child, are one of the few people who should get 
    OPV, your doctor or nurse will tell you when the
    
    [[Page 52597]]
    
    vaccine should be given. Speak to your doctor or nurse about the risks 
    of vaccine-associated polio before getting OPV.
        OPV may be given at the same time as other vaccines.
    
    5. Some People Should Not Get Oral Polio Vaccine (OPV) or Should Wait
    
        Do not use OPV drops if your child, you, or anyone who takes care 
    of your child:
    
     Can't fight infections
     Is taking long-term steroids
     Has cancer
     Has AIDS or HIV infection.
    
        Do not use OPV drops if you or anyone who takes care of your child 
    never had polio vaccine.
        Anyone who has had a severe allergic reaction to a dose of OPV 
    should not get another dose.
        People who are moderately or severely ill at the time the 
    immunization is scheduled should usually wait until they recover before 
    getting OPV.
    
    6. What Are the Risks From Oral Polio Vaccine (OPV)?
    
        OPV can, in rare circumstances, actually cause polio. This is why 
    it is not recommended for routine use any more. It caused several cases 
    of polio each year (about 1 case for every 2.4 million doses of 
    vaccine) during the years it was used. The oral vaccine can cause polio 
    in children who get OPV or in people who are in close contact with 
    them. The risk of polio is higher with the first dose than with later 
    doses.
    
    7. What if There Is a Serious Reaction?
    
    What Should I Look for?
        Look for any unusual condition, such as a serious allergic 
    reaction, high fever, behavior changes, or signs of paralysis.
        If a serious allergic reaction occurred, it would happen within a 
    few minutes to a few hours after the vaccination. Signs of a serious 
    allergic reaction can include difficulty breathing, hoarseness or 
    wheezing, hives, paleness, weakness, a fast heart beat or dizziness.
        If paralysis were to occur, symptoms might include severe muscle 
    aches and spasms, or loss of movement in an arm or leg. This could 
    happen from about a week to about a month after the vaccination.
    What Should I Do?
         Call a doctor or get the person to a doctor right away.
         Tell your doctor what happened, the date and time it 
    happened, and when the vaccination was given.
         Ask your doctor, nurse, or health department to file a 
    Vaccine Adverse Event Reporting System (VAERS) form, or call VAERS 
    yourself at 1-800-822-7967.
    
    8. The National Vaccine Injury Compensation Program
    
        In the rare event that you or your child has a serious reaction to 
    a vaccine, there is a federal program that can help pay for the care of 
    those who have been harmed.
        For details about the National Vaccine Injury Compensation Program, 
    call 1-800-338-2382 or visit the program's website at http://
    www.hrsa.gov/bhpr/vicp.
    
    9. How Can I Learn More?
    
         Ask your doctor or nurse. They can give you the vaccine 
    package insert or suggest other sources of information.
         Call your local or state health department's immunization 
    program.
         Contact the Centers for Disease Control and Prevention 
    (CDC)
    
    --Call 1-800-232-2522 (English)
    --Call 1-800-232-0233 (Espanol)
    --Visit the National Immunization Program's website at http://
    www.cdc.gov/nip
    
    U.S. Department of Health and Human Services, Centers for Disease 
    Control and Prevention, National Immunization Program
    
    Vaccine Information Statement, Polio--OPV Supplement (1/1/2000) 
    (Proposed), 42 U.S.C. 300aa-26
    
        Dated: September 23, 1999.
    Thena M. Durham,
    Acting Associate Director for Management and Operations, Centers for 
    Disease Control and Prevention (CDC).
    [FR Doc. 99-25276 Filed 9-28-99; 8:45 am]
    BILLING CODE 4163-18-P
    
    
    

Document Information

Published:
09/29/1999
Department:
Centers for Disease Control and Prevention
Entry Type:
Notice
Action:
Notice with comment period.
Document Number:
99-25276
Dates:
Written comments are invited and must be received on or before November 29, 1999.
Pages:
52596-52597 (2 pages)
PDF File:
99-25276.pdf